MetaCap

HUTCHMED (China) (HCM) vs Arcus Biosciences (RCUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

HUTCHMED (China) (HCM) has outperformed Arcus Biosciences (RCUS) over the past year, losing 5.6% versus a loss of 29.2%. Over five years, HCM leads with a -62.4% price change compared with -66.3% for RCUS. HUTCHMED (China) is the larger company by market cap ($2.30 billion vs $2.25 billion), about 1.0 times the size, while Arcus Biosciences is growing revenue faster (-4.3% vs -13.0%).

HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -142.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HCM-5.57%RCUS-29.16%
+47%+7%-33%
Nov 21, 20251 yearNov 20, 2026
HCM-56.97%RCUS-67.15%
+20%-35%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HCM versus RCUS key metrics
MetricHCMRCUS
Share price$13.22$15.62
Market cap$2.30B$2.25B
1-day change-1.71%-1.01%
YTD return-0.83%-34.45%
1-year return-5.57%-29.16%
5-year return-62.42%-66.31%
P/E ratio (TTM)132.20—
Forward P/E51.00—
EPS (TTM)$0.10$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$548.51M$247.00M
Revenue growth (YoY)-12.96%-4.26%
Net income (latest FY)$456.91M$-353.00M
Gross margin38.68%—
Operating margin-7.14%-156.28%
Net margin83.30%-142.91%
52-week high$16.33$31.74
52-week low$9.77$15.56
Distance from 52-week high-19.04%-50.78%
Analyst consensusnonestrong_buy
Avg. price target upside+59.91%+162.48%
Average volume64.48K1.85M
Shares outstanding173.81M143.99M
Employees1,790601
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HCM has outperformed RCUS by 23.6 percentage points over the past year.
  • HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.
  • Arcus Biosciences grew revenue faster in its latest fiscal year (-4.26% vs -12.96%).

About HUTCHMED (China)

HCM stock →

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

HCM vs RCUS FAQ

Which is bigger, HUTCHMED (China) or Arcus Biosciences?

HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.30B compared with $2.25B for Arcus Biosciences (RCUS).

Which stock has performed better over the past year, HCM or RCUS?

HCM returned -5.57% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.

Are HUTCHMED (China) and Arcus Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons